Objective
Acute graft-versus-host disease (GVHD) and leukemia relapse cause 75% of the mortality of patients having undergone allogeneic hematopoietic cell transplantation (allo-HCT). A better understanding of signalling in immune cells, tissue specific cell types and leukemia cells is key to develop novel therapies against GVHD and leukemia relapse. The ambitious overall goal of AlloCure is to identify the pathogenic events that initiate GVHD (1), maintain therapy-refractory GVHD (2) and mediate immune escape causing leukemia relapse (3). To address these high risk/high gain questions novel methods and developments across disciplines are required. (1) I hypothesize that a loss of to date unexplored intestinal enteroendocrine cells promotes GVHD initiation. To study these small cell subsets, we will use reporter genes and novel imaging methods to systematically evaluate their fate and signalling during intestinal GVHD. (2) Signalling propagating refractory GVHD is not well-understood. Our phospho-proteomics data set from corticosteroid- and ruxolitinib-refractory GVHD patients will instruct selective analysis of kinase activation in immune cells and enterocytes by using genetic Cre-lox-based and pharmacological approaches. (3) I have shown that leukemia-derived lactic acid inhibits glycolysis and MEK/ERK signalling in T cells, thereby impairing graft-versus-leukemia (GVL) effects. Here, I will decipher which other leukemia-derived metabolites mediate pathogenic signalling in immune cells and test if oncogenic signalling in leukemia cells drives immunosuppressive metabolite production. To enhance GVL we will inhibit pathogenic kinase activation in leukemia cells and myeloid suppressor cells. Using high risk/high gain approaches in a combination of murine and human studies AlloCure aims to develop individualized therapeutic strategies to interfere with pathogenic signalling responsible for GVHD or leukemia relapse to reduce the mortality rate of patients undergoing allo-HCT.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicineemergency medicinegraft versus host disease
- medical and health sciencesclinical medicinetransplantation
- medical and health sciencesclinical medicineoncologyleukemia
You need to log in or register to use this function
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Topic(s)
Funding Scheme
HORIZON-ERC - HORIZON ERC GrantsHost institution
79106 Freiburg
Germany